EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study

Margaret Haney iD, Tse-Hwei Choo, Amy Tiersten, Frances R Levin, Alex Grassetti, Natasha DeSilva, Caroline A Arout iD, Diana Martinez

Cannabis & Cannabinoid Research · 2025

DOI: 10.1089/can.2025.0028 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cannabis & Cannabinoid Research, 2025. Verfasst von Margaret Haney und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bridged-Ring Compounds, Cannabidiol, Dronabinol. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Taxane-induced peripheral neuropathy (TIPN) is experienced by most patients with breast cancer, and there is no efficacious treatment. In pre-clinical studies, co-administration of two constituents of cannabis, Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), synergistically reduces TIPN. Materials and Methods: The goal of this 8-week, double-blind, randomized pilot study, conducted from 2019 to 2021, was to test the feasibility and tolerability of oral cannabis (100 mg CBD: 5 mg THC, TID) relative to placebo on pain resulting from TIPN. Participants with painful TIPN completed daily questionnaires online about their pain, sleep, and medication use, and weekly questionnaires on neuropathy.

Results

All participants (12 women; 51 ± 6 years) randomized to placebo ( n = 6) or active ( n = 6) cannabis capsules completed the trial. Participants in both medication groups requested dose reductions (mean ± SEM capsules/day: placebo: 2.4 ± 0.4; active: 2.0 ± 0.4). In a preliminary evaluation of efficacy, measures of pain, pain interference, sleep, and functional well-being significantly improved over time ( p < 0.03), but participants receiving cannabis had significantly higher ratings of neuropathy at each week ( p < 0.035) and lower ratings of functional well-being in the last 3 weeks of treatment compared with participants receiving placebo ( p < 0.02). Similarly, cannabis significantly worsened ratings of sleep and pain interference relative to placebo ( p < 0.05).

Discussion

This study demonstrates that: (1) double-blind, placebo-controlled testing of cannabis capsules in this dose range is feasible and well tolerated in women with TIPN and (2) ratings of pain, neuropathy, and well-being significantly improved over 8 weeks, but cannabis significantly worsened several endpoints relative to placebo. These findings highlight the necessity of placebo control when assessing the therapeutic utility of cannabis. Although there was no signal of efficacy herein, a fully powered study testing a range of cannabis doses for TIPN is warranted, given its impact on most patients with breast cancer, promising pre-clinical data, and the widespread use of cannabis among patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBridged-Ring CompoundsCannabidiolDronabinolMedical MarijuanaPeripheral Nervous System DiseasesTaxoidsFemaleHumansMiddle AgedAdministration, OralBreast NeoplasmsDouble-Blind MethodPilot Projects

Stichwörter der Autor:innen

cancercannabidiolmedical marijuananeuropathic paintetrahydrocannabinol

Substanzen

Antineoplastic AgentsBridged-Ring CompoundsCannabidiolDronabinolMedical MarijuanataxaneTaxoids

Autor:innen und Institutionen

  • Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York, USA.
  • Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Margaret Haney, Caroline A Arout

Zitieren

APA

Haney, M., Choo, T. H., Tiersten, A., Levin, F. R., Grassetti, A., DeSilva, N., Arout, C. A., & Martinez, D. (2025). Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study. Cannabis & Cannabinoid Research. https://doi.org/10.1089/can.2025.0028

Vancouver

Haney M, Choo TH, Tiersten A, Levin FR, Grassetti A, DeSilva N, et al. Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study. Cannabis & Cannabinoid Research. 2025. doi:10.1089/can.2025.0028

BibTeX
@article{Haney2025,
  author = {Haney, Margaret and Choo, Tse-Hwei and Tiersten, Amy and Levin, Frances R and Grassetti, Alex and DeSilva, Natasha and Arout, Caroline A and Martinez, Diana},
  title = {Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study},
  journal = {Cannabis & Cannabinoid Research},
  year = {2025},
  doi = {10.1089/can.2025.0028}
}
Kostenlos starten →